Rosetta Launches Next-Generation Cancer Diagnostic, Not Alone in Exploring microRNAs as Biomarkers
December 16, 2010
Rosetta Launches Next-Generation Cancer Diagnostic, Not Alone in Exploring microRNAs as Biomarkers
A review of the National Cancer Institute's online clearinghouse for clinical trial information shows that more than a dozen groups worldwide are either conducting or preparing to launch studies examining miRNA signatures in humans with a variety of diseases.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Rosetta Genomics, Prime Health Reach Deal for Coverage of MiRview Mets2 Assay
May 20, 2013 / GenomeWeb Daily News - NIH Awards $400K to Fund Three microRNA Research Grants in May
May 20, 2013 / Gene Silencing News - NIH Announces Two Funding Opportunities with Potential for Non-Coding RNA Research
May 2, 2013 / Gene Silencing News - NIH Awards Nearly $2M in microRNA Research Grants
April 18, 2013 / Gene Silencing News - Rosetta Settles Dispute over Lab Sale
April 18, 2013 / Gene Silencing News